Six niche contract research organizations (CROs) have formed an alliance to provide pharmaceutical and biotech organizations a comprehensive suite of services from concept to IND.
Over the past several years, pharmaceutical and biotech companies have experienced increased pressures in drug discovery and development. With many blockbuster drugs nearing the patent-cliff, there is growing pressure to develop new lead compounds, reduce time spent in discovery and bring drugs to market faster with less cost.
Many sponsor companies are turning to outsourcing to increase efficiency and decrease cost throughout the drug development process. They are aligning themselves with fewer CROs that offer a more comprehensive selection of studies. Sponsors are finding that while there are conveniences dealing with large, full-service CROs, quality, expertise and timeliness often suffer.
next IND is a strategic alliance of niche CROs, each filling a key step in the drug development process and combining to create a comprehensive suite of services to take a drug from concept to IND.
Many industry analysts have predicted the next wave of pharmaceutical R&D outsourcing will be strategic CRO alliances like next IND. These alliances offer sponsors the convenience of a full-service CRO without sacrificing therapeutic expertise.
next IND is comprised of six CROs – all widely considered experts in their respective areas. In the non-clinical space Cedarburg Hauser offers substance process development and manufacturing services, XenoTech offers in vitro drug metabolism services, Formurex offers preformulation and formulation services as well as GMP manufacturing, Xenometrics offers toxicology services, and KCAS offers bioanalytical services. Clinical research services are provided by Vince & Associates.
With the services provided by these six CROs, next IND is able to offer a streamlined approach to drug development, saving sponsors time and money.